Livzon Pharmaceutical Group Inc. (SHE:000513)

SHE:000513 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 5, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021
Market Capitalization	34,928	30,704	28,292	27,456	32,307	33,156
Market Cap Growth	-2.81%	8.53%	3.04%	-15.02%	-2.56%	19.91%
Enterprise Value	28,969	24,773	22,700	22,297	27,114	27,086
Last Close Price	41.36	36.93	32.80	29.19	34.71	34.08
PE Ratio	17.29	14.90	14.48	14.38	18.19	19.33
Forward PE	16.54	15.83	17.25	16.36	18.28	21.60
PS Ratio	2.96	2.60	2.28	2.17	2.68	3.15
PB Ratio	2.34	2.06	1.92	1.84	2.26	2.43
P/TBV Ratio	2.67	2.30	2.10	2.08	2.56	2.82
P/FCF Ratio	14.26	12.75	11.65	14.98	54.46	21.90
P/OCF Ratio	11.14	10.31	8.71	9.90	16.98	15.35
PEG Ratio	-	0.29	0.29	0.29	0.29	0.29
EV/Sales Ratio	2.45	2.10	1.83	1.77	2.25	2.58
EV/EBITDA Ratio	9.03	8.03	8.28	8.70	11.58	11.19
EV/EBIT Ratio	11.01	9.77	11.81	11.54	14.14	13.35
EV/FCF Ratio	11.83	10.29	9.35	12.17	45.71	17.89
Debt / Equity Ratio	0.24	0.27	0.28	0.24	0.19	0.14
Debt / EBITDA Ratio	1.13	1.28	1.50	1.40	1.14	0.80
Debt / FCF Ratio	1.48	1.65	1.71	1.98	4.54	1.27
Asset Turnover	0.47	0.48	0.50	0.54	0.56	0.55
Inventory Turnover	2.29	2.09	2.33	2.47	2.74	2.82
Quick Ratio	1.93	1.87	1.86	1.97	1.83	2.13
Current Ratio	2.19	2.15	2.13	2.30	2.12	2.40
Return on Equity (ROE)	16.94%	15.53%	12.78%	13.37%	13.97%	16.45%
Return on Assets (ROA)	6.61%	6.40%	4.81%	5.11%	5.58%	6.58%
Return on Capital (ROIC)	8.84%	8.39%	6.41%	6.79%	7.36%	8.69%
Return on Capital Employed (ROCE)	15.70%	15.10%	11.30%	11.10%	12.40%	14.00%
Earnings Yield	6.22%	6.71%	6.91%	6.95%	5.50%	5.17%
FCF Yield	7.01%	7.85%	8.58%	6.67%	1.84%	4.57%
Dividend Yield	2.64%	2.98%	4.12%	5.48%	3.75%	3.67%
Payout Ratio	74.94%	65.03%	81.36%	83.33%	70.81%	64.14%
Buyback Yield / Dilution	2.04%	1.10%	0.56%	0.04%	0.25%	-0.41%
Total Shareholder Return	4.68%	4.08%	4.68%	5.52%	4.00%	3.26%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.